Nothing like data showing significant death reduction can better support prostate cancer screening

PSA Screening in Prostate Cancer

Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...

Prostate cancer screening: what can we learn from randomised trials?

In this article, the principle of randomised trials are first described and then prostate cancer screening trials published to date are evaluated based on these principles. A summary of the randomised prostate cancer screening is provided. The conclusion that can be made from the results of the screening trials, as well as limitations of the evidence and open questions are outlined in the end.

Is something better than nothing?

In July 2000 I spent 3 weeks in Haiti on a medical student elective. Eager to work in a new country and experience a new culture, I’d read about Haitian culture and history. This was my first exposure to medicine outside of North America. People warned me: “Haiti? Be careful! You can’t trust anyone there! They’re so poor, they’ll take anything they can get their hands on!” I was confident commo...

Prostate cancer screening.

Screening for prostate cancer.

In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved t...